Hidetaka Fukue

The replacement therapy with quantitative infusion of fVIII concentrate and its merit on plasma level and total dose.

On the basis of the in vitro stability of factor VIII concentrate at room temperature, continuous intravenous infusion of the remedey could be utilized as a hemostatic management for a major surgey in hemophilia A. One hour prior to the amputation of the left femule of the patient, 55u/kg of Hemofil H® as a bolus pretreatment and thereafter continuous infusion by quantitative pump with 2.7u/kg/hr of Hemofil H® for 3 days, 2.2u/kg/hr for next 5 days, 1.6u/kg/hr for the third period of 6 days, and 0.8u/kg/hr for last period of 4 days were followed. Consequently it was able to stabilize the hemostatic level of plasma VIII:C with the preparation, of which amount was less than that of previous cases with major surgical operations managed by bolus infusions of the similar preparation.Thus, this continuous infusion method applied on major surgery of hemophiliacs might be recommended as a thrapeutic way being safer and more economic than the conventional method, because no excess amount of factor VIII concentrate are infused.